INFU Quote, Financials, Valuation and Earnings

ResMed, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of 26.1%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat ResMed, Inc.'s return on equity of 25.6%.

InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 55.87%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.38%. Given that InfuSystem Holdings, Inc. has higher upside potential than ResMed, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than ResMed, Inc..

InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.

InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.60 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. InfuSystem Holdings, Inc.'s net income of $2.3M is lower than ResMed, Inc.'s net income of $348.5M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.84x while ResMed, Inc.'s PE ratio is 25.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.37x versus 6.84x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -862.39%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat VolitionRX Ltd.'s return on equity of --.

InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 55.87%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that VolitionRX Ltd. has higher upside potential than InfuSystem Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than InfuSystem Holdings, Inc..

InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.84x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.37x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -1037.17%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Catheter Precision, Inc.'s return on equity of -192.05%.

InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 55.87%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 2034.9%. Given that Catheter Precision, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than InfuSystem Holdings, Inc..

InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.84x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.37x versus 8.37x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of 3.93%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 55.87%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Xtant Medical Holdings, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than InfuSystem Holdings, Inc..

InfuSystem Holdings, Inc. has a beta of 1.708, which suggesting that the stock is 70.763% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 34.84x while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.37x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.